Moore Capital Management, LP Regeneron Pharmaceuticals, Inc. Transaction History

Moore Capital Management, LP

  • $4.85 Billion
  • Q3 2024

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024
SELL
$883.2 - $1071.19 $3.71 Million - $4.5 Million
-4,200 Reduced 24.71%
12,800 $13.5 Million
Q1 2024

May 15, 2024
BUY
$902.69 - $993.35 $5.42 Million - $5.96 Million
6,000 Added 54.55%
17,000 $16.4 Million
Q4 2023

Feb 14, 2024
BUY
$775.18 - $881.7 $8.53 Million - $9.7 Million
11,000 New
11,000 $9.66 Million
Q1 2023

May 15, 2023
BUY
$680.49 - $826.97 $6.8 Million - $8.27 Million
10,000 New
10,000 $8.22 Million
Q3 2022

Nov 14, 2022
BUY
$573.97 - $724.32 $10.5 Million - $13.2 Million
18,264 Added 76.98%
41,991 $28.9 Million
Q2 2022

Aug 15, 2022
BUY
$548.35 - $738.84 $3.58 Million - $4.82 Million
6,521 Added 37.9%
23,727 $14 Million
Q1 2022

May 16, 2022
BUY
$595.12 - $698.43 $10.2 Million - $12 Million
17,206 New
17,206 $12 Million
Q3 2021

Nov 15, 2021
SELL
$574.03 - $680.96 $24.5 Million - $29 Million
-42,640 Closed
0 $0
Q2 2021

Aug 16, 2021
BUY
$472.8 - $558.54 $20.2 Million - $23.8 Million
42,640 New
42,640 $23.8 Million
Q1 2021

May 17, 2021
SELL
$446.73 - $548.2 $10.2 Million - $12.5 Million
-22,804 Closed
0 $0
Q4 2020

Feb 16, 2021
BUY
$478.3 - $607.98 $10.9 Million - $13.9 Million
22,804 New
22,804 $11 Million

Others Institutions Holding REGN

# of Institutions
1,534
Shares Held
83.6M
Call Options Held
1.22M
Put Options Held
1.51M
View Full List

About REGENERON PHARMACEUTICALS, INC.

REGN Quotes by TradingView
  • Ticker REGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,190,000
  • Market Cap $76.6B
  • Description
  • Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...
More about REGN
Track This Portfolio

Track Moore Capital Management, LP Portfolio

Follow Moore Capital Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Moore Capital Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Moore Capital Management, LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email